常山藥業股票討論區

Despite a high P/S ratio, Hebei Changshan Biochemical Pharmaceutical's recent poor growth signals potential investor risk. High P/S ratio, alongside declining revenues, may indicate overvaluation and potential disappointment for shareholders.